Effects of the serotonin(2A/2C) receptor agonist and antagonist on phencyclidine-induced dopamine release in rat medial prefrontal cortex

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 23, Issue 7, 1999, Pages 1259-1275

  Kuroki, Toshihide ^a   Kawahara, Takeshi ^b   Yonezawa, Yuji ^b   Tashiro, Nobutada ^b  

^a SAGA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

DOI; Microdialysis; N methyl D aspartate receptor; Ritanserin; Schizophrenia

Indexed keywords

DIZOCILPINE; DOPAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; RITANSERIN; SEROTONIN; SEROTONIN 2A AGONIST; SEROTONIN 2A ANTAGONIST; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; AMPHETAMINE DERIVATIVE; PSYCHEDELIC AGENT; SEROTONIN AGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG EFFECT; DRUG INDUCED DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PATHOGENESIS; PREFRONTAL CORTEX; PSYCHOSIS; RAT; SCHIZOPHRENIA; VENTRAL TEGMENTUM; ANIMAL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION; WISTAR RAT;

AMPHETAMINES; ANIMALS; DOPAMINE; HALLUCINOGENS; MALE; PHENCYCLIDINE; PREFRONTAL CORTEX; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN AGONISTS;

EID: 0033201512     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(99)00065-2     Document Type: Article

References (59)

1. 2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology 20: 92-96, 1999.
2. Adams, B. and Moghaddam, B. (1998) Cortical dopamine neurotransmission is temporally dissociated from the cortical and locomotor effects of phencyclidine. J. Neurosci. 18:5545-5554.
3. Aghajanian, G.K. and Marek, G.J. (1997) Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology, 36: 589-599.
4. Andersson, J.L., Nomikos, G.G., Marcus, M., Hertel, P., Mathé, J.M. and Svensson, T.H. (1995) Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic systems. Naunyn-Schmiedeberg's Arch. Pharmacol. 352: 374-385.
5. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience, 40: 399-412.
6. Cleghorn, J.M., Garnett, E.S., Nahmias, C., Firnau, G., Brown, G.M., Kaplan, R., Szechtman, H. and Szechtman, B. (1989) Increased frontal and reduced parietal glucose metabolism in acute untreated schizophrenia. Psychiatry Res. 28:119-133.
7. Davis, K.L., Kahn, R.S., Ko, G. and Davidson, M. (1991) Dopamine in Schizophrenia: A review and reconceptualization. Am. J. Psychiatry 148:1474-1486.
8. Deutch, A.Y., Tam, S.Y., Freeman, A.S., Bowers Jr. M.B. and Roth, R.H. (1987) Mesolimbic and mesocortical dopamine activation induced by phencyclidine: Contrasting pattern to striatal response. Eur. J. Pharmacol. 134: 257-264.
9. Etou, K., Kuroki, T., Kawahara, T., Yonezawa, Y., Tashiro, N. and Uchimura, H. (1998) Ceruletide inhibits phencyclidine-induced dopamine and serotonin release in rat medial prefrontal cortex. Pharmacol. Biochem. Behav. 61: 427-434.
10. French, E.D., Levenson, S. and Ceci, A. (1990) Characterization of the actions of phencyclidine on midbrain dopamine neurons. NIDA Res. Monograph 95: 255-263.
11. Giros, B., El Mestikawy, S., Godinot, N., Zheng, K., Han, H., Yang-Feng, T. and Caron, M.G. (1992) Cloning, pharmacological, and chromosome assignment of the human dopamine transporter. Mol. Pharmacol. 42: 383-390.
12. 2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35:2505-2511.
13. 2 receptor agonists. Eur. J. Pharmacol. 264: 325-330.
14. Hondo, H., Yonezawa, Y., Nakahara, T., Nakamura, K., Hirano, M., Uchimura, H. and Tashiro, N. (1994) Effect of phencyclidine on dopamine release in the rat prefrontal cortex: An in vivo microdialysis study. Brain Res. 633: 337-342; 1994.
15. 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat striatum. Brain Res. 698: 204-208.
16. 2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Natl. Acad. Sci. USA 95: 735-740.
17. Javitt, D.C. and Zukin, S.R. (1991) Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148:1301-1308.
18. Jentsch, J.D., Tran, A., Taylor, J.R. and Roth, R. (1998) Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: Behavioral and neurochemical evidence. Psychopharmacology 138: 89-95.
19. Kane, J., Honigfeld, G., Singer, J. and Meltzer, H.Y. (1988) Clozapine for the treatment-resistant schizophrenic: A double blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45: 789-796.
20. Kitaichi, K., Yamada, K., Hasegawa, T., Furukawa, H. and Nabeshima, T. (1994) Effects of risperidone on phencyclidine-induced behaviors: Comparison with haloperidol and ritanserin. Jpn. J. Pharmacol. 66:181-189.
21. Krebs-Thomson, K., Lehmann-Masten, V., Naiem, S., Paulus, M.P. and Geyer, M.A. (1998) Modulation of phencyclidine-induced changes in locomotor activity and patterns in rats by serotonin. Eur. J. Pharmacol. 343:135-143.
22. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger, G.R., Bowers, M.B. Jr. and Charney, D.S. (1993) Subanesthetic effects of the non-competitive NMDA antagonist, ketamine, in humans. Arch. Gen. Psychiatry 51:199-214.
23. 1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex. Brain Res. 743: 357-361.
24. Kuroki, T., Meltzer, H.Y. and Ichikawa, J. (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288: 774-781.
25. Lahti, A.C., Holcomb, H.H., Medoff, D.R. and Tamminga, C.A. (1995) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6: 862-872.
26. 2 receptors. Psychopharmacology 112: S40-S54.
27. Maddox, V.H., Godefroi, E.F. and Parcell, R.F. (1965) The synthesis of phencyclidine and other 1-arylcyclohexylamines. J. Med. Chem. 8: 230-235.
28. 2A receptors. Eur. J. Pharmacol. 280: R9-R11.
29. Mccullough, L.D. and Salamone, J.D. (1992) Increases in extracellular dopamine levels and locomotor activity after direct injection of phencyclidine into the nucleus accumbens. Brain Res. 577: 1-9.
30. Moghaddam, B., Adams, B., Verma, A. and Daly, D. (1997) Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruption associated with the prefrontal cortex. J. Neurosci. 17: 2921-2927.
31. Moghaddam, B. and Bunney, B.S. (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: An in vivo microdialysis study. J. Neurochem. 54: 1755-1760.
32. 2 receptors in the rat brain. Neuroscience 54: 701-717.
33. Murphy, B.L., Arnsten, A.F., Goldman-Rakic, P.S. and Roth, R.H. (1996) Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc. Natl. Sci. USA 93: 1325-1329.
34. Nishijima, K., Kashiwa, A., Hashimoto, A., Iwama, H., Umino, A. and Nishikawa, T. (1996) Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis. Synapse 22: 304-312.
35. Nomikos, G.G., Iurlo, M., Andersson, J.L., Kimura, K. and Svensson, T.H. (1994) Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 115:147-156.
36. Ögren, S.O. and Goldstein, M. (1994) Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology 11: 167-177.
37. Parellada, E., Catafau, A.M., Bernardo, M., Lomena, F., Gonzalez-Monclus, E. and Setoain, J. (1994) Prefrontal dysfunction in young acute neuroleptic-naive schizophrenic patients: A resting and activation SPECT study. (1994) Psychiatry Res. 55: 131-139.
38. Paxinos, G and Watson, C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
39. Pehek, E.A. (1996) Local infusion of the serotonin antagonists ritanserin or ICS 205,930 increases in vivo dopamine release in the rat medial prefrontal cortex. Synapse 24: 12-18.
40. Pehek, E.A. and Bi, Y. (1997) Ritanserin administration potentiates amphetamine-stimulated dopamine release in the rat prefrontal cortex. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 21: 671-682.
41. Pessia, M., Jiang, Z.G., North, R.A. and Johnson, S.W. (1994) Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res. 654: 324-330.
42. 2C receptors. Mol. Brain Res. 23: 163-178, 1994.
43. Roth, B.L. and Meltzer, H.Y. (1995) The role of serotonin in schizophrenia. In: Psychopharmacology: The Fourth Generation of Progress. F.E. Bloom and D.J. Kupfer (Eds.), pp. 1215-1227, Raven Press, New York.
44. 2 receptor agonist (DOI) disrupt the non-cognitive performance of rats in a working memory task. J. Psychopharmacol. 12: 177-185.
45. B receptor agonists and antagonists. Brain Res 630: 28-31.
46. 2A receptor blockade. J. Pharmacol. Exp. Ther. 277: 1541-1549.
47. 2 receptors reduces the increase in extracellular concentrations of dopamine produced by amphetamine analogue, 3,4-methylenedioxymethamphetamine. J. Neurochem. 62:1382-1389.
48. 2 receptor antagonist MDL 100,907, as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther. 266: 684-691.
49. Steinpreis, R.E. (1996) The behavioral and neurochemical effects of phencyclidine in humans and animals: Some implications for modeling psychosis. Behav. Brain Res. 74: 45-55.
50. 1-adrenoreceptor antagonism. J. Clin. Psychopharmacol. 15: 11S-18S.
51. Tricklebank, M.D., Singh, L., Oles, R.J., Preston, C. and Iverson, S.D. (1989) The behavioural effects of MK-801: A comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur. J. Pharmacol. 167:127-135.
52. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45-50.
53. 18F]fluorodeoxyglucose (FDG). Eur. Neuropsychopharmacol. 7: 9-24.
54. Westerink, B.H.C., Tuntler, J., Damsma, G., Rollema, H. and De Vries, J.B. (1987) The use of tetrodotoxin for the characterization of drug-enhanced dopamine release unconscious rats studied by brain dialysis. Naunyn-Schmiedeberg's Arch. Pharmacol. 336:502-507.
55. Williams, G.V. and Golman-Rakic, P.S. (1995) Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature, 376: 572-575.
56. 2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse, 27: 79-82.
57. 2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J. Pharmacol. Exp. Ther. 282: 699-706.
58. 2 agonist, DOI, on 5-HT neuronal firing in the dorsal raphe nucleus and 5-HT release and metabolism in the frontal cortex. Br. J. Pharmacol. 99: 221-222.
59. Yonezawa, Y., Kuroki, T., Kawahara, T., Tashiro, N. and Uchimura, H. (1998) Involvement of γ-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex. Eur. J. Pharmacol. 341: 45-56.